Galera Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Galera Therapeutics generated cash of -$44,848,000, which is less than the previous year. Cash used in financing activities reached the amount of $31,496,000 last year. Net change in cash is therefore $13,941,000.
Cash Flow
| 2017 | -23.40M | 23.51M | 0 |
|---|---|---|---|
| 2018 | -22.16M | -59.03M | 89.84M |
| 2019 | -46.66M | -27.82M | 78.03M |
| 2020 | -59.53M | 36.54M | 20.50M |
| 2021 | -67.95M | 5.23M | 66.70M |
| 2022 | -43.42M | 23.99M | 3.88M |
| 2023 | -44.84M | 27.29M | 31.49M |
GRTX Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 4.31M | 19.85M | 15.87M | 18.35M | 14.81M | 6.16M | 6.06M |
Operating activities | |||||||
Net income | -59.08M | -62.22M | -80.53M | -74.21M | -51.93M | -23.67M | -23.54M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 259K | 114K | 778K | 368K | 267K | 127K | 84K |
Stock-based compensation expense | 5.56M | 7.16M | 7.23M | 5.53M | 2.39M | 0 | 726K |
| Deferred income tax benefit | 5.56M | 7.16M | 7.23M | 5.53M | 2.39M | 0 | 726K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | -258K | -307K | 0 | 629K | 0 | -63K |
Inventories | 0 | 258K | 307K | 0 | -629K | 0 | 0 |
Accounts payable | -2.20M | -1.46M | -101K | 1.20M | 77K | 1.58M | -652K |
Cash generated by operating activities | -44.84M | -43.42M | -67.95M | -59.53M | -46.66M | -22.16M | -23.40M |
Investing activities | |||||||
Purchases Of Investments | -22.64M | -59.89M | -71.97M | -67.74M | -123.19M | -71.19M | -9.91M |
Investments In Property Plant And Equipment | -59K | -25K | -283K | -457K | -633K | -347K | -319K |
Acquisitions Net | 0 | -24.01K | -5.52K | -37.00K | 27.19K | 0 | 0 |
Cash generated by investing activities | 27.29M | 23.99M | 5.23M | 36.54M | -27.82M | -59.03M | 23.51M |
Financing activities | |||||||
Common Stock Issued | 29.29M | 3.80M | 7.94M | 506K | 58.02M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -57.5M | -20M | 0 | 0 | 0 |
Cash used in financing activities | 31.49M | 3.88M | 66.70M | 20.50M | 78.03M | 89.84M | 0 |
Net Change In Cash | 13.94M | -15.54M | 3.98M | -2.48M | 3.54M | 8.64M | 106K |
Cash at end of period | 18.25M | 4.31M | 19.85M | 15.87M | 18.35M | 14.81M | 6.16M |
| Data source | Data source | Data source | Data source | Data source |